Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03744741 · ClinicalTrials.gov registry record
HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study
A clinical trial, sponsored by Inflammatix.
- Completed
- Registry status
- 585
- Enrollment target
NCT03744741: Completed study, sponsored by Inflammatix.
NCT03744741 is a clinical trial that has completed, run by Inflammatix. The registered enrollment target is 585 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03744741 has completed, sponsored by Inflammatix.
- COMPLETED
- Registry status
- 585 participants
- Enrollment target
Study Summary
This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections. The primary endpoint of the study is to prospectively validate the HostDx Sepsis test for infections. As a secondary endpoint the correlation of participant prognosis and gene expression results in the HostDx Sepsis test will be validated. Participants presenting to the emergency departments of enrolling sites with a suspected infection and 1 vital signs OR suspected sepsis and 2 vital sign changes as stated in the protocol are meeting enrollment criteria
Primary Outcome
Percent agreement of HostDx Sepsis bacterial readout with clinical adjudication by physician 30 days after enrollment for the presence of a bacterial infection
Interventions
- DIAGNOSTIC_TEST HostDx Sepsis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 585 participants |
| Start Date | 2018-07-23 |
| Est. Completion | 2020-01-20 |
What the finished NCT03744741 record still lists
NCT03744741 is an observational study that tracks outcomes without assigning an intervention. The registered 585 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 1 intervention - of which HostDx Sepsis is the first listed.
NCT03744741 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03744741 about?
NCT03744741 is a clinical study titled "HostDx Sepsis in the Diagnosis and Prognosis of Emergency Department Patients With Suspected Infections: a Multicenter Pilot Study". This study will analyze gene expression data (HostDx Sepsis test) from blood samples collected from participants with suspected infections. The primary endpoint of the study is to prospectively validate the HostDx Sepsis test for infections. As a secondary endpoint the correlation of participant pro...
What is the current status of trial NCT03744741?
This trial is currently completed. The enrollment target is 585 participants. The study started on 2018-07-23. Estimated completion is 2020-01-20.
What interventions are being tested in trial NCT03744741?
The interventions under investigation include: HostDx Sepsis (DIAGNOSTIC_TEST).
Who is sponsoring clinical trial NCT03744741?
This trial is sponsored by Inflammatix, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02803957 · 585 participants · NA
Randomized Trial of the Neochord DS1000 System Versus Open Surgical Repair
- NCT06680869 · 585 participants · Phase 3
Early Amiodarone in Shockable Cardiac Arrest
- NCT04134260 · 586 participants · Phase 3
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
- NCT06100770 · 586 participants
Aveir AR Coverage With Evidence Development (CED) Study
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI